Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 43 for “"bortezomib"”.
-
Mechanisms of Astrocyte Contribution to Bortezomib-Induced Peripheral Neuropathy
<p>Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and other non-solid malignancies, alone or in combination with other chemotherapy drugs. Like other chemotherapeutic agents, bortezomib treatment is frequently accompanied by chemotherapy-induced peripheral neuropathy …
-
Loperamide enhances bortezomib-mediated cell death in colon cancer cells
… cell death induced by loperamide plus bortezomib is neither apoptosis not autophagic cell death 14 2. Intracellular Ca2+ influx is involved in the combined treatment-induced vacuolation 27 3. Combined treatment with loperamide and bortezomib induces ER stress, and CHOP is critically …
-
Nutlin-3 sensitizes cancer cells to bortezomib via induction of paraptosis-associated cell death
… is considered a target for cancer therapies. Bortezomib, the first FAD approved proteasome inhibitor, is now in the clinic to effectively treat multiple myeloma and mantle cell lymphoma, but its efficacy in solid tumors is not satisfactory. In this study, we show that the nutlin-3, a …
-
Investigation of the intrinsic mechanism of drug resistance in multiple myeloma
… with a focus on resistance in the context of bortezomib treatment. The aims of this thesis were to examine multidrug resistance pumps as a mechanism of resistance in MM, to investigate the contribution of p53 signalling perturbations in resistance mechanism in MM, to study the AMPK pathway as …
-
Neurochemical characterization of primary sensory neurons in a rat model of bortezomic-induced peripheral neuropathy
… vinca alkaloids, but also newer agents such as bortezomib. Bortezomib (VELCADE) is a boronic acid dipeptide, which causes a selective blockade of proteasome activity. Bortezomib-induced peripheral neuropathy is an important clinical complication, often difficult to manage or reverse, whose …
-
Proteasome inhibition in chronic myeloid leukaemia
… against CML cell lines. We demonstrate that bortezomib is antiproliferative and induces apoptosis in CD34+ cells taken at diagnosis from patients with CP CML cells, with an LD50 below concentrations achieved in vivo. We also demonstrate for the first time that CD34+38- CML cells, representing …
-
Cost utility and budget impact analysis of bortezomib and lenalidomide for the treatment of relapsed/refractory multiple myeloma in the South African public health sector
… plus low-dose dexamethasone (LEN/DEX) and bortezomib monotherapy (BORT). The clinical effectiveness of both regimens for second-line treatment of RRMM was reported in the MM009/010 and the APEX studies, respectively, where each regimen was compared against dexamethasone monotherapy. Given …
-
Mechanistic study on the therapeutic strategy to enhance glioma cell death through inhibition of proteasome and lysosome
… mechanism-based drugs are currently developed. Bortezomib (BZ), a proteasome inhibitor, and chloroquine (CQ), a lysosomotropic agent, can disrupt cellular protein homeostasis (proteostasis) via interruption of protein degradation systems, including proteasome and lysosome. In part I, we …
-
Proteasome Inhibition As A Potential Anti-Breast Cancer Therapy: Mechanisms Of Action And Resistance-Reversing Strategies
… of the FDA-approved proteasome inhibitor bortezomib depends on an increase in intracellular calcium levels as calcium chelation abrogates its induced AMPK activation. Finally, bortezomib-mediated upregulation in CaMKKβ levels is due to its enhanced protein synthesis.</p> <p>It has been …
-
The Role of the Ubiquitin-Proteasome System in the Regulation of Nuclear Hormone Receptor-Dependent Transcription
… und ist Ziel in der Krebstherapie (Bortezomib). Verschiedene Indizien sprechen für eine wesentliche Rolle des UPS in Steroidhormonrezeptor-vermittelter Transkriptionskontrolle. Das Ziel dieser Arbeit war die Untersuchung der UPS-Funktion in Glucocorticoidrezeptor- (GR-) und im …
-
Overcoming Tumor Drug Resistance By Activating Amp-Activated Protein Kinase And Destabilizing Oncoproteins
… myeloma cell models in which paired parental bortezomib-sensitive multiple myeloma cells and their bortezomib-resistant counterparts generated by chronic drug exposure were used. In this study, I found that paired bortezomib-sensitive and -resistant multiple myeloma cells were about equally …
-
Multiple Myeloma and Its Treatment Alter Peripheral Nervous System Structure and Function
… limiting treatment. Proteasome inhibitor, bortezomib (Velcade<sup>®</sup>) is an effective treatment of multiple myeloma (MM), but often provokes the development of small fiber, sensory, distal neuropathy in patients. MM is caused by malignancy of plasma cells, which indirectly compromises …
-
Investigating new roles of the ubiquitin proteasome system in cell death and innate immune signalling
… results were seen with proteasome inhibitor Bortezomib which is used clinically in the treatment of multiple myeloma. This effect is interesting considering that IL10 is a growth factor for myeloma cells and some patients treated with Bortezomib develop a refractory response to treatment and …
-
Mathematical modelling of bone remodelling at the cellular level and the interaction between myeloma cells and the bone microenvironment
… bone disease, including bisphosphonates, bortezomib and the inhibition of TGF-β. The simulation confirms that treatments with bisphosphonates and bortezomib can reduce the tumour burden and bone destruction, which is consistent with clinical observations. However, the inhibition of TGF-β …
-
biological treatment options of multiple myeloma
… with steroids, and immunomodulatory therapies. Bortezomib, Carfilzomib, and Ixazomib are examples of proteasome inhibitors. Bortezomib is the predominant choice in treatment regimens. The basic action of proteosome inhibitors is to inhibit the degradation of proteins within the cell nucleus …
-
Mechanisms Underlying The Heterogeneous Sensitivities of Cancer Cells to Proteasome Inhibitors
… using the FDA-approved proteasome inhibitor bortezomib (Velcade®) in solid tumor cells, we demonstrated that perhaps the most critical response to proteasome inhibition is repression of global protein synthesis by phosphorylation of the eukaryotic initiation factor 2-α subunit (eIF2α). In a …
-
New Roles for the Integrated Stress Response in Cancer and Proteostasis
… to the chemotherapy and proteasome inhibitor, bortezomib. We found this second finding to be mechanistically linked to a previously-undescribed role for the ISR in regulating the microtubule cytoskeleton to promote the removal of aggregated proteins. As a second goal of this project we sought …
-
Exploring the link between RAG1 Cellular Distribution and Components of the CRL4DCAF1 E3 Ligase
… after incubation with the proteasome inhibitor, bortezomib, revealed significantly reduced puncta compared to non-treated cells. Unlike FLRAG1, cRAG1 half-life is not extended by proteasome inhibition, so we assume this effect is indirect. Co-expression of DCAF1 with FLRAG1 caused a decrease in …
-
Estudio de la apoptosis y autofagia como parte del mecanismo antineoplásico de la vitamina D en el sarcoma de Kaposi
… a una regulación no genómica de esta quinasa. El Bortezomib, inhibidor del proteasoma y de la activación de NF-ĸB, disminuyó la proliferación celular e indujo apoptosis por un mecanismo similar a los agonistas del VDR en células vGPCR. Proceso acompañado además por la activación del factor de …
Page 1 of 3